The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
Yoshihiko Saito - One of the best experts on this subject based on the ideXlab platform.
-
azelnidipine Plus Olmesartan versus Amlodipine Plus Olmesartan on arterial stiffness and cardiac function in hypertensive patients a randomized trial
Drug Design Development and Therapy, 2013Co-Authors: Takeshi Takami, Yoshihiko SaitoAbstract:Purpose To compare the long-term effects of Olmesartan combined with either azelnidipine or Amlodipine on central blood pressure (CBP), left ventricular (LV) mass index (LVMI), LV diastolic function (e′ velocity, E/e′ ratio, E/A ratio) and arterial stiffness (brachial-ankle pulse wave velocity [baPWV] and augmentation index normalized for a heart rate of 75 bpm [AIx]).
-
Effects of Azelnidipine Plus Olmesartan versus Amlodipine Plus Olmesartan on central blood pressure and left ventricular mass index: the AORTA study
Vascular health and risk management, 2011Co-Authors: Takeshi Takami, Yoshihiko SaitoAbstract:PURPOSE: The aim of this study was to compare the effects of Olmesartan combined with either azelnidipine or Amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients. PATIENT AND METHODS: Patients with brachial systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg received Olmesartan monotherapy (20 mg daily) for 12 weeks. The patients were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg daily) or Amlodipine (5 mg daily) (25 patients/group) for a further 24 weeks. CBP and LVMI were measured at baseline and at the end of the study. RESULTS: Baseline characteristics were similar in both groups. The decrease in brachial BP was similar in both groups. CBP and LVMI decreased significantly in both groups (both, P < 0.001). However, the decreases in CBP and LVMI were significantly greater with Olmesartan/azelnidipine than with Olmesartan/Amlodipine (CBP, P < 0.001; LVMI, P = 0.002). CONCLUSIONS: These findings indicate that Olmesartan/azelnidipine had greater effects on CBP and LVMI than did Olmesartan/Amlodipine, even though the reduction in brachial BP was similar in both groups. These differential effects on CBP and LVMI may have important implications for cardiovascular risk reduction.
Takeshi Takami - One of the best experts on this subject based on the ideXlab platform.
-
azelnidipine Plus Olmesartan versus Amlodipine Plus Olmesartan on arterial stiffness and cardiac function in hypertensive patients a randomized trial
Drug Design Development and Therapy, 2013Co-Authors: Takeshi Takami, Yoshihiko SaitoAbstract:Purpose To compare the long-term effects of Olmesartan combined with either azelnidipine or Amlodipine on central blood pressure (CBP), left ventricular (LV) mass index (LVMI), LV diastolic function (e′ velocity, E/e′ ratio, E/A ratio) and arterial stiffness (brachial-ankle pulse wave velocity [baPWV] and augmentation index normalized for a heart rate of 75 bpm [AIx]).
-
Effects of Azelnidipine Plus Olmesartan versus Amlodipine Plus Olmesartan on central blood pressure and left ventricular mass index: the AORTA study
Vascular health and risk management, 2011Co-Authors: Takeshi Takami, Yoshihiko SaitoAbstract:PURPOSE: The aim of this study was to compare the effects of Olmesartan combined with either azelnidipine or Amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients. PATIENT AND METHODS: Patients with brachial systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg received Olmesartan monotherapy (20 mg daily) for 12 weeks. The patients were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg daily) or Amlodipine (5 mg daily) (25 patients/group) for a further 24 weeks. CBP and LVMI were measured at baseline and at the end of the study. RESULTS: Baseline characteristics were similar in both groups. The decrease in brachial BP was similar in both groups. CBP and LVMI decreased significantly in both groups (both, P < 0.001). However, the decreases in CBP and LVMI were significantly greater with Olmesartan/azelnidipine than with Olmesartan/Amlodipine (CBP, P < 0.001; LVMI, P = 0.002). CONCLUSIONS: These findings indicate that Olmesartan/azelnidipine had greater effects on CBP and LVMI than did Olmesartan/Amlodipine, even though the reduction in brachial BP was similar in both groups. These differential effects on CBP and LVMI may have important implications for cardiovascular risk reduction.
Reinilde Heyrman - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of Amlodipine Plus Olmesartan medoxomil in patients with difficult to treat hypertension
Journal of Human Hypertension, 2010Co-Authors: Steven G Chrysant, Jj Lee, Michael Melino, Subhas S Karki, Reinilde HeyrmanAbstract:Hypertension is particularly prevalent in patients aged ⩾65 years, those with a body mass index ⩾30 kg m−2, Blacks and those with type II diabetes. Here we report a prespecified secondary analysis of the efficacy of Amlodipine (10 mg day−1), Olmesartan medoxomil (40 mg day−1), a combination of the two and placebo in these subgroups. Patients were randomized to treatment for 8 weeks. The primary efficacy endpoint was the change from baseline in mean seated diastolic blood pressure (DBP). Secondary efficacy endpoints included the change from baseline in mean seated systolic BP (SBP), proportions of patients achieving BP goal (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes), and the number and percentage of patients achieving a range of BP targets. Safety and tolerability of Amlodipine 5 and 10 mg, Olmesartan medoxomil 10, 20 and 40 mg, and all possible combinations of the two were also assessed. For each prespecified subgroup, all active treatments resulted in significant BP reductions from baseline (P<0.05). The antihypertensive effect of the combination of Amlodipine+Olmesartan medoxomil was generally greater than the constituent Amlodipine or Olmesartan medoxomil monotherapies, regardless of subgroup. In general, more patients receiving combination therapy achieved BP goal than those treated with monotherapies. The safety and tolerability of combinations were similar to monotherapies across the subgroups. These results suggest that the combination of Amlodipine+Olmesartan medoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations.
Steven G Chrysant - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of Amlodipine Plus Olmesartan medoxomil in patients with difficult to treat hypertension
Journal of Human Hypertension, 2010Co-Authors: Steven G Chrysant, Jj Lee, Michael Melino, Subhas S Karki, Reinilde HeyrmanAbstract:Hypertension is particularly prevalent in patients aged ⩾65 years, those with a body mass index ⩾30 kg m−2, Blacks and those with type II diabetes. Here we report a prespecified secondary analysis of the efficacy of Amlodipine (10 mg day−1), Olmesartan medoxomil (40 mg day−1), a combination of the two and placebo in these subgroups. Patients were randomized to treatment for 8 weeks. The primary efficacy endpoint was the change from baseline in mean seated diastolic blood pressure (DBP). Secondary efficacy endpoints included the change from baseline in mean seated systolic BP (SBP), proportions of patients achieving BP goal (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes), and the number and percentage of patients achieving a range of BP targets. Safety and tolerability of Amlodipine 5 and 10 mg, Olmesartan medoxomil 10, 20 and 40 mg, and all possible combinations of the two were also assessed. For each prespecified subgroup, all active treatments resulted in significant BP reductions from baseline (P<0.05). The antihypertensive effect of the combination of Amlodipine+Olmesartan medoxomil was generally greater than the constituent Amlodipine or Olmesartan medoxomil monotherapies, regardless of subgroup. In general, more patients receiving combination therapy achieved BP goal than those treated with monotherapies. The safety and tolerability of combinations were similar to monotherapies across the subgroups. These results suggest that the combination of Amlodipine+Olmesartan medoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations.
Jj Lee - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of Amlodipine Plus Olmesartan medoxomil in patients with difficult to treat hypertension
Journal of Human Hypertension, 2010Co-Authors: Steven G Chrysant, Jj Lee, Michael Melino, Subhas S Karki, Reinilde HeyrmanAbstract:Hypertension is particularly prevalent in patients aged ⩾65 years, those with a body mass index ⩾30 kg m−2, Blacks and those with type II diabetes. Here we report a prespecified secondary analysis of the efficacy of Amlodipine (10 mg day−1), Olmesartan medoxomil (40 mg day−1), a combination of the two and placebo in these subgroups. Patients were randomized to treatment for 8 weeks. The primary efficacy endpoint was the change from baseline in mean seated diastolic blood pressure (DBP). Secondary efficacy endpoints included the change from baseline in mean seated systolic BP (SBP), proportions of patients achieving BP goal (<140/90 mm Hg or <130/80 mm Hg in patients with diabetes), and the number and percentage of patients achieving a range of BP targets. Safety and tolerability of Amlodipine 5 and 10 mg, Olmesartan medoxomil 10, 20 and 40 mg, and all possible combinations of the two were also assessed. For each prespecified subgroup, all active treatments resulted in significant BP reductions from baseline (P<0.05). The antihypertensive effect of the combination of Amlodipine+Olmesartan medoxomil was generally greater than the constituent Amlodipine or Olmesartan medoxomil monotherapies, regardless of subgroup. In general, more patients receiving combination therapy achieved BP goal than those treated with monotherapies. The safety and tolerability of combinations were similar to monotherapies across the subgroups. These results suggest that the combination of Amlodipine+Olmesartan medoxomil provides a safe and effective option for the treatment of hypertension in challenging patient populations.